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Abstract
The pathogenesis of Tuberculous meningitis (TBM) is poorly understood,
but contemporary molecular biology technologies have allowed for recent
improvements in our understanding of TBM. For instance, neutrophils
appear to play a significant role in the immunopathogenesis of TBM, and
either a paucity or an excess of inflammation can be detrimental in TBM.
Further, severity of HIV-associated immunosuppression is an important
determinant of inflammatory response; patients with the advanced
immunosuppression (CD4+ T-cell count of <150 cells/μL) having higher
CSF neutrophils, greater CSF cytokine concentrations and higher mortality
than those with CD4+ T-cell counts > 150 cells/μL. Host genetics may also
influence outcomes with LT4AH genotype predicting inflammatory
phenotype, steroid responsiveness and survival in Vietnamese adults with
TBM. Whist in Indonesia, CSF tryptophan level was a predictor of survival,
suggesting tryptophan metabolism may be important in TBM pathogenesis.
These varying responses mean that we must consider whether a
“one-size-fits-all” approach to anti-bacillary or immunomodulatory treatment
in TBM is truly the best way forward. Of course, to allow for proper
treatment, early and rapid diagnosis of TBM must occur. Diagnosis has
always been a challenge but the field of TB diagnosis is evolving, with
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 always been a challenge but the field of TB diagnosis is evolving, with
sensitivities of at least 70% now possible in less than two hours with
GeneXpert MTB/Rif Ultra. In addition, advanced molecular techniques such
as CRISPR-MTB and metagenomic next generation sequencing may hold
promise for TBM diagnosis. Host-based biomarkers and signatures are
being further evaluated in childhood and adult TBM as adjunctive
biomarkers as even with improved molecular assays, cases are still missed.
A better grasp of host and pathogen behaviour may lead to improved
diagnostics, targeted immunotherapy, and possibly biomarker-based,
patient-specific treatment regimens.
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Introduction
The pathogenesis of Tuberculous meningitis (TBM) is poorly 
understood. Mechanisms by which Mycobacteria disseminate 
from lung to the brain, key factors driving a dysregulated host 
response, and the pathogen specific factors influencing presen-
tation and severity, compared to other forms of TB, are not well 
described. In recent years application of contemporary molecular 
biology ‘omics’ techniques to clinical samples, greater 
availability of advanced neuroradiology, emphasis on immune- 
mediated contributions to pathology, and use of refined experi-
mental models of TBM have better illuminated its pathogenesis. 
A better grasp of these processes may also lead to improved 
diagnostics, targeted immunotherapy as well as a biomarker-
based, patient-specific approach to personalized treatment. 
Diagnosis has been traditional insensitive (AFB smear) 
and slow (culture). This has improved with the addition of 
GeneXpert MTB/Rif (Xpert) which gave sensitivities similar to 
culture in 2 hours (versus 2–4 weeks with culture). Subsequently, 
GeneXpert MTB/Rif Ultra (Ultra), a re-engineered version, has 
shown better sensitivities than culture in some settings. Yet, 
none of these technologies has adequate negative predictive value 
to ‘rule-out’ TBM. In this article we review important recently 
published studies that have informed our current understanding 
of TBM pathogenesis and diagnostics. We do not seek to present 
a comprehensive review of the history of TBM pathogen-
esis and diagnostics as a number of detailed papers that have 
addressed this recently1–3. Rather we provide a commentary of 
key studies published within the last 5 years and summarise 
knowledge gaps and future considerations to enable progress 
in the field.
TBM pathogenesis
Dissemination to the central nervous system
Understanding of the microbial and immune processes that 
allow M. tuberculosis to disseminate from the respiratory 
epithelium to reach the meninges remains incomplete2,4. The 
foundations of what is known were laid through natural history 
and autopsy studies in the pre-chemotherapy era. The necessary 
steps to develop TBM include the pathogen surviving its initial 
encounter with the innate immune system at the respiratory epi-
thelium and establishment of primary infection in the lung 
parenchyma with characteristic granulomatous inflammation5–7. 
Spread beyond the lungs likely occurs through the blood and 
may be preceded by local invasion to the lymphatic system. This 
bloodborne spread highlights the possibility of coincident mil-
iary TB in cases of TBM, especially common in children and 
people living with HIV (PLWHIV)8,9. The contemporaneous 
nature of TBM and miliary TB refutes the “Rich focus” 
model (of a single meningeal/sub-cortical granuloma ruptur-
ing years after initial haematogenous dissemination discharging 
acid-fast bacilli into the sub-arachnoid space)10.
Host immune response to TB infection in the CNS
The host immune response to TB bacilli in the sub-arachnoid 
space gives rise to a granulomatous inflammation predomi-
nantly affecting the basal meninges. Inflammatory exudates may 
obstruct the passage of cerebrospinal fluid (CSF), leading to 
hydrocephalus. Small and medium-sized intracerebral arteries 
can become inflamed and occluded, leading to cerebral inf-
arcts. The majority of TBM pathology is believed to result 
from the host inflammatory response;2 several pro- and 
anti-inflammatory cytokines such as tumour necrosis 
factor-α (TNF-α), interferon-γ (IFN-γ), interleukin (IL) 1β, 
IL-6, IL-8, and IL-10 are induced in TBM11,12. Disequilibrium of 
pro- and anti-inflammatory cytokines influence the severity and 
course of TBM, Figure 12,13.
The long-standing belief that excessive inflammation is the 
cause of death in TBM was brought into question by a recent 
immunopathogenesis study in Vietnam. In HIV-negative adults, 
associations between death and both lower CSF cytokine 
concentrations and lower CSF leucocyte counts (median 59 
× 103 cells/mL (IQR 13–240 × 103 cells/mL) in those who died 
versus 135 × 103 cells/mL (IQR, 48–298 × 103 cells/mL) in 
survivors) were noted14. These data support the notion that 
poor outcome from TBM, in the context of immunosuppressive 
treatment (adjunctive corticosteroids), is associated with an inad-
equate pretreatment inflammatory response in HIV-negative 
individuals. A separate study of 120 Vietnamese adults with 
TBM from a randomized controlled trial of adjunctive aspirin 
treatment investigated concentrations of host protective lipid 
mediators (specialized proresolving mediators, SPMs) in CSF. 
Prostaglandins and cysteinyl leukotrienes were found to be 
reduced in more severe cases, while the lipoxygenase 5-derived 
13-series resolvin (RvT)2, RvT4, and 15-epi-lipoxin B4, 
were significantly increased in survivors. These data suggest 
SPMs may play an important role in TBM pathogenesis15.
Among 608 Indonesian adults with suspected TBM, higher 
CSF and blood neutrophil counts (HR 1.10 (95%CI 1.04–1.16) 
per 10% increase and HR 1.06 per 109 neutrophils/L increase; 
(95% CI 1.03–1.10), respectively) were associated with 
mortality16. Flow-cytometry on blood in a subset of 160 
HIV-negative adults with TBM showed lower αβT and γδT 
cells, NK cells and MAIT cells in TBM subjects compared to 26 
pulmonary TB adults (2.4 to 4-fold, all p < 0.05) and 27 healthy 
controls (2.7-7.6-fold, p < 0.001), but higher neutrophils and 
classical monocytes (2.3 - 3.0-fold, p < 0.001). CSF flow cytom-
etry of TBM patients showed a predominance of αβT and 
NK cells, associated with better survival, as well as the 
presence of MAIT cells, previously undescribed in CSF17. 
Indonesian HIV-negative TBM patients showed a strong mye-
loid blood response and a remarkably broad lymphoid CSF 
response including innate lymphocytes, however there was little 
correlation between blood and CSF compartments17.
Host genetic and metabolic factors. 
Leukotriene A4 hydrolase (LTA4H) catalyzes the final step in 
the synthesis of leukotriene B4 (LTB4), a potent chemoattract-
ant and proinflammatory eicosanoid. In Vietnamese adults, a sin-
gle-nucleotide polymorphism rs17525495 in the LTA4H gene 
results in either a hyper- or hypo-inflammatory state, correlating 
with TBM severity, corticosteroid responsiveness and survival in 
HIV-negative adults, Figure 214. Individuals with the TT genotype 
have improved survival versus those with CC or CT genotype 
possibly due to inadequate inflammatory response, there is 
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Figure 1. Illustrative summary of the pathogenesis of tuberculous meningitis (TBM). Reproduced with permission from author and 
Journal of Leukocyte Biology2. A: Mycobacterium tuberculosis bacilli (M.tb) disseminate from the primary site of infection in the lung to seed 
the brain. The bacilli traverse the blood brain barrier (BBB) and blood cerebrospinal fluid barrier (BCSFB) through various virulence factors 
that enable the invasion of and migration through cerebral vascular endothelial cells, or are carried into the CNS by infected peripheral innate 
immune cells. B: In the CNS antigen recognition and internalization by microglia, neurons and astrocytes occurs, mediated by numerous 
host genetic factors. C: The resulting immune response stimulates the release of proinflammatory cytokines and chemokines and other 
immune mediators that contribute to the breakdown of the BBB and the influx of innate and adaptive immune cells from the periphery. D: A 
prolific inflammatory response ensues. The inflammatory exudate in the basal cisterns contributes to cerebral vascular pathology and the 
development of hydrocephalus and raised intracranial pressure. Vasogenic edema due to an influx of proteins through the leaky BBB, and 
cytotoxic edema as a result of cellular damage contribute to the raised pressure. The overall decrease in cerebral blood flow puts the brain 
at risk of ischemia, infarction and poor patient outcomes. In some cases the infection is controlled in discrete tuberculomas or abscesses, 
which may resolve with treatment and time.
concern for potential harm caused by adjunctive dexametha-
sone in these cases. Interestingly, LTA4H genotype did not 
predict outcomes in Indonesian adults with TBM, but there was 
a trend towards improved survival with TT genotype compared 
to CC or CT genotype, Figure 216. A clinical trial is 
currently underway in Vietnam (NCT03100786) to evalu-
ate LTA4H genotype-directed corticosteroid therapy, an excit-
ing example of personalised medicine in TBM18. Others factors 
associated with death in a Cox proportional hazards regression 
model of the large Vietnamese clinical trials cohort were higher 
MRC disease severity grade, older age, previous TB, focal 
neurology and not receiving adjunctive steroids19.
Although prior studies have considered sodium, glucose and 
lactate as related to TBM pathogenesis, recent interest has 
focused on tryptophan. This amino acid required for protein 
biosynthesis is a precursor to serotonin and melatonin (serot-
onin pathway) and kynurenine and quinolinic acid (kynurenine 
pathway). The latter is stimulated at the expense of the former 
by pro-inflammatory cytokine such as IL-6, TNF-alpha and 
IFN-gamma via indoleamine 2, 3-dioxygenase. In a recent 
study of serum and CSF metabolites, low levels of tryptophan 
were associated with survival20. One theory regarding this asso-
ciation could be the neuroprotective effects of the associated 
kynurenine pathway downstream metabolites. Either this 
pathway, or the 11 genetic foci related to CSF tryptophan 
metabolism could have novel clinical implications for TBM20.
HIV co-infection and immune reconstitution inflammatory 
syndrome
HIV infection is a strong independent predictor of death 
from TBM (hazard ratio, 3.94; 95% confidence interval 
(CI), 2.79–5.56)19. The role of adjunctive corticosteroids in HIV-
associated TBM is inconclusive (relative risk of death with 
adjunctive steroids, 0.78; 95% CI, 0.59 to 1.04; P=0.08)21 and a 
randomized placebo-controlled trial is underway (NCT03092817) 
to address the use of steroids in HIV-associated TBM. Patho-
genesis studies in PLWHIV are required to identify the unique 
pathogenic determinants of poor prognosis. Thuong et al. 
compared the pretreatment CSF cells and cytokine profiles of 
764 HIV-positive and HIV-negative participants in Vietnamese 
TBM clinical trials. HIV-positive individuals had higher mean 
CSF neutrophil percentage (17% vs 5%; P < .0001) and glo-
bal cytokine expression (aside from IL-10 which inhibits 
response to M. tuberculosis) than their HIV-negative counter-
parts. PLWHIV with CD4+ T-cell counts <150 cells/μL showed 
higher median CSF neutrophil percentage (25%), cytokine 
concentrations and 9-month mortality (44%) than those with a 
CD4+ T-cell count ≥150 cells/μL (neutrophils 10%; P=.021, 
mortality 13%) and patients without HIV infection (neutrophils 
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5%; P<.0001, mortality 18%)14. These findings, amongst 
others, suggest a role for neutrophils in the immunopathogenesis 
of HIV-associated TBM22.
Marais et al. conducted longitudinal analyses of paired blood 
and CSF samples in South Africans with HIV-associated 
TBM, describing the relationships between the development of 
immune reconstitution inflammatory syndrome (IRIS) and CSF 
leucocytes, the concentrations of >30 blood and CSF inflamma-
tory mediators, and blood transcriptional profiles. They found 
TBM-associated CNS IRIS to have an inflammatory signa-
ture characterized by neutrophil and inflammasome-mediated 
proinflammatory responses23,24. The neutrophil-dependent 
inflammatory activation could be detected in peripheral blood 
before the start of TB treatment and therefore has potential to 
predict who will develop IRIS.
Pathogenesis of TBM in childhood
The protective role of CD4+ and CD8+ T lymphocytes is 
essential, along with macrophages, to isolate and engulf 
mycobacteria to form a granuloma. This could explain 1) the 
vulnerability to TBM of young children and PLWHIV when 
T-cell mediated immunity is sub-optimal 2) the protective 
effect of the BCG-primed T-cell response in childhood TBM 
meningitis and 3) the association between TBM and genetic 
polymorphisms influencing the early, innate immune response25.
Donald and Schoeman have highlighted that miliary TB and 
TBM are closely related, particularly in young children, where 
tubercles of different sizes and ages have been described on 
the meninges and confirmed by magnetic resonance imag-
ing (MRI)8,26. In children, miliary TB and TBM develop most 
often within 3 months of primary infection, when fresh anatomic 
Figure 2. Kaplan-Meier survival curves stratified by LTA4H genotype. Figures A and B show survival in 763 patients with tuberculous 
meningitis in Vietnam14, with human immunodeficiency virus (HIV) infection (A), and without HIV infection (B). In HIV-infected patients, case-
fatality rates were 34.8% (16 of 46) in those with TT genotype, 42.1% (61 of 145) in CT genotype, and 38.8% (52 of 134) in CC genotype. In 
HIV-uninfected patients, case-fatality rates were 7.1% (3 of 42) in TT, 21.4% (40 of 187) in CT, and 18.7% (39 of 209) in CC. Figures C and 
D show survival in 375 patients with tuberculous meningitis in Indonesia16. These patients are HIV-uninfected with severe (GCS ≤ 13) (C) or 
milder (GCS 14–15) disease (D). In a recessive model, TT genotype versus CT/TT combined had HR 0.81 (95% CI 0.41-1.62, p = .550) in 
severe and 0.31 (95% CI 0.04-2.25, p = .156) in milder disease.
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changes are still found in the primary lung focus27. Miliary 
TB, a severe form of symptomatic haematogenous dissemina-
tion arising in people who lack the ability to control the infec-
tion in the lungs (frequently children or adults with advanced 
HIV disease or other risk factors), may therefore be the precursor 
for TBM by increasing the likelihood of M.tb seeding the menin-
ges, cerebral cortex or choroid plexus which subsequently 
precipitates the development of TBM.
Brain injury markers. 
In lumbar CSF of children with TBM, high levels of pro-
teins S100B and neuron-specific enolase (NSE) and their 
increase over time (along with an increase in glial fibril-
lary acidic protein (GFAP)) were associated with poor 
outcomes28. Neuromarker concentrations increased over time 
in those who died (whilst inflammatory markers decreased), 
and were overall highest in those with cerebral infarction. In 
ventricular CSF of children with TBM, transcriptomic signa-
tures showed neuro-excititoxicity driven by glutamate release 
and NMDA binding and receptor uptake as well as upregu-
lation of genes associated with nitric oxide, cytochrome c, 
myelin basic protein, tau, and amyloid. These mechanisms 
have been described in neurodegenerative conditions such as 
Alzhiemer’s and Huntington’s disease and traumatic brain 
injury and may occur following ischaemia in TBM29.
Neuroimaging in pathogenesis studies
Technical advances and increasing availability of imaging 
modalities has recently enabled research in which imaging is 
used to assess pathogenic mechanisms in TBM in vivo in ani-
mal and human subjects. In a blood and CSF biomarker study of 
childhood TBM tuberculomas, magnetic resonance imag-
ing has been used to note an association between tuberculomas 
and elevated interleukin (IL) 12p40, interferon-inducible 
protein 10, and monocyte chemoattractant protein 1 concentra-
tions, whereas infarcts were associated with elevated TNF- α, 
macrophage inflammatory protein 1α, IL-6, and IL-828. Specific 
sequences can also be used to describe morphology of struc-
tural damage and correlate this to meaningful clinical measures. 
For instance poorer Diffusion Tensor Imaging (DTI) parameters 
of white matter integrity in the anterior cingulate gyrus 
parahippocampal gyrus and globus pallidus are associated with 
worse neuropsychological performance30. A further study by the 
same group used Diffeomorphic Anatomical Registration Through 
Exponentiated Lie Algebra (DARTEL) voxel-based morphom-
etry (VBM) to assess the integrity of grey matter in these same 
TBM patients31. Patients with TBM performed significantly 
poorer on the digit symbol, similarities, block design, matrix rea-
soning, and letter-number sequencing subtests of the Wechsler 
Adult Intelligence Scale compared to healthy adults. These 
changes correlated with smaller grey matter volumes in the 
right thalamus, right superior temporal gyrus, right precuneus, 
right middle temporal gyrus, left putamen, right caudate nucleus, 
and right middle temporal gyrus31. These studies suggest 
that structural damage can be cortical as well as subcortical 
which may in turn be related to degree of long-term impairment.
A rabbit model study of childhood TBM, utilized ionized 
calcium binding adapter molecule (Iba-1) to approximate 
microglial activation with flurodeoxyglucose-positron emission 
tomography (FDG-PET) and demonstrated the presence of acti-
vated microglia and macrophages localized to TB lesions32. In 
humans, case reports and a prospective study have advocated 
the use of FDG-PET as a diagnostic tool, as it has been effec-
tive in detecting extra-cranial evidence supportive of a TBM 
diagnosis33–35. The role of FDG-PET in unravelling time course 
of inflammation in TBM remains to be seen, although it has 
played a role in understanding Alzheimer’s, a disease in which, 
similar to TBM, inflammation plays a key pathogenic role36,37.
Pathogen factors: bacillary load, pathogen strain and 
virulence factors
TBM patients generally have low bacterial loads in CSF which 
causes difficulties in both diagnosis and ability to study bacterial 
load evolution-related pathophysiology. The time-to-positivity of 
a culture and cycle threshold (Ct) of nucleic acid amplification 
tests such as GeneXpert MTB/Rif (Xpert) can provide an indi-
cation of likely bacterial burden38. Over 50% of diagnosed cases 
are microbiologically undetectable and defined as ‘probable’ or 
‘possible’ TBM which obviously limits this approach39. Marais 
et al. showed that in patients where M.tb was cultured from 
CSF taken before and after two weeks of anti-tuberculosis 
treatment, there was a 9.3-fold increased risk of subsequently 
developing TBM-IRIS, although the sample size is small 
with 15 TBM-IRIS patients compared with 6 non-TBM-IRIS 
patients40. Thuong et al. found that among 692 Vietnamese 
adults with TBM, pre-treatment CSF M.tb load (by Xpert Ct) 
was correlated with increased CSF neutrophil counts, increased 
cytokine production, and new neurological events after treatment 
initiation, but not death38.
In addition, epidemiological trends of M.tb lineage from 
TBM (n=73) and pulmonary TB (n=220) patients in Thai-
land showed that the Indo-Oceanic lineage is more frequently 
found in TBM patients (41% versus 13% in PTB)41. This asso-
ciation did not hold true in Indonesia, though specific genetic 
variations were identified which were associated with TB 
phenotype, including one (Rv0218) whose encoded protein 
may play a role in host-pathogen interaction42.
Host-pathogen interactions
It is estimated that the global burden of latent TB infec-
tion (LTBI) is approximately 23.0% (95% CI 20.4%–26.4%), 
amounting to approximately 1.7 billion people43. Innate immune 
responses are critical to control TB infection yet also contrib-
ute to tissue damage. This delicate balance is illustrated in the 
damage response framework which provides a theory of micro-
bial pathogenesis that incorporates the contributions of both 
host and microbe to host damage that stems from host-microbe 
interaction44,45. This framework likely applies to TBM based 
on evidence of both failed immunity and excessive inflamma-
tion being linked to increased TBM pathology, see Figure 346–48. 
Both the microbe and the host contribute to host damage and 
where an individual patient’s immune response lies on the 
continuum of the damage response framework parabola deter-
mines the nature of the disease process14,38,49. The current 
one-size-fits-all approach to TBM treatment fails to recognize 
divergent pathologies and may explain the poor outcomes in 
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certain populations. Being able to identify where on the parabola 
an individual lies and tailoring therapy to achieve the optimal 
milieu is an approach that warrants further investigation.
TBM diagnostics
Host-based diagnostic biomarkers
Traditional diagnostic techniques for TBM include CSF smear 
microscopy for acid fast bacilli (rapid and cheap but insensi-
tive in most settings, 10–15%) and CSF culture (improved 
sensitivity of 50–60% but results in 2–6 weeks with a 
biosafety lab level three requirement)3. Given the limitations 
of traditional, diagnostic tests for TBM that focus on bacillary 
detection, there is interest in the utilization of host-based diag-
nostic biomarkers for diagnosis of TBM, Figure 4. Adenosine 
deaminase (ADA), produced by lymphocytes, is an important 
regulator of follicular helper T-cells. ADA is commonly used 
for diagnosis of TB from other, typically extra-pulmonary 
locations and numerous studies have considered ADA for 
diagnosis of TBM50. One 2017 meta-analysis found ADA to 
have a pooled sensitivity of 89% (95% CI 84–92%) with pooled 
specificity 91% (95% CI, 87–93%)50. Yet ADA use for TBM 
diagnosis has been limited by the high cost of the test, required 
sophisticated lab infrastructure, study heterogeneity, inadequate 
negative predictive values, and variable test performance.
A number of studies have considered unstimulated CSF inter-
feron gamma (IFN-γ) levels as a diagnostic test, in general, a 
high number of false positive results has limited the utility of 
CSF IFN-γ51,52. For instance, in one study of 39 controls (n=12 
viral, n=16 purulent, n=11 cryptococcal meningitis) and 30 
subjects with TBM while median IFN-γ levels where higher 
amongst subjects with TBM, diagnostic accuracy was inad-
equate52. At the strongest cut-point (81pg/mL) determined by 
receiver operator curve analysis, positive predictive value was 
only 81% with positive results occurring in 2/12 (17%) with 
viral meningitis, 3/16 (19%) with purulent meningitis, and 
1/11(9%) with cryptococcal meningitis52.
Interferon gamma release assays (IGRAs) are commonly used 
to infer LTBI. A 2016 meta-analysis of six studies perform-
ing CSF IGRA’s found a pooled sensitivity and specificity of 
77% (95% CI 69%-84%) and 88% (95% CI 74%-95%), respec-
tively, for TB meningitis, though reference standards varied 
by study53. Limitations of IGRA include high cost, the need 
for advanced lab infrastructure, frequent “indeterminate” 
results, and false positives associated with other causes of 
meningitis. Additional host biomarkers including delta-like lig-
and 1, vitamin D binding protein, and fetuin have been evalu-
ated in CSF though none were found to have satisfactory 
performance54. Numerous CSF antibodies to M.tb in CSF has 
also been evaluated. Huang and colleagues found pooled sen-
sitivities of 91% (95% CI 71–98%) for anti-M37Ra across 
five studies, 84% (95% CI 71–92%) for anti-antigen-5 across 
eight studies, and 84% (95% CI 71–92%) across 12 stud-
ies for anti-M37Rv, again using a variety of reference standards 
(making the pooled estimates somewhat flawed)55. Use of 
Figure 3. Outcomes of the host – M. tuberculosis interaction depicted by the basic parabola of the damage-response framework. On 
the left side of the parabola, shaded in blue, the immune system fails to limit mycobacterial growth and invasion which results in host damage. 
On the right side, shaded in red, the immune response is excessive and the resultant inflammation and host-damage. The proportion of the 
parabola lying below the black line represents disease latency, which is not associated with clinically evident host damage. On the blue side 
therapeutic interventions could be targeted at stimulating an immune response, whilst on the red side therapeutic interventions could aim to 
dampen immune response.
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blood antibody assays are discouraged for the diagnosis 
of TB, and their utility in CSF is limited by heterogeneity 
and the lack of a uniform reference standard across research 
studies as well as a lack of commercial assays.
Biomarkers in children
The often-dismal outcome of TBM is contributed to by delayed 
diagnosis and/or initiation of treatment, especially in high burden 
settings4. Currently available diagnostic tests perform-
ance is especially poor in young children with TBM. Thus, 
diagnosis of childhood TBM is mostly based on a combi-
nation of clinical findings, CSF analysis and radiological 
findings57. Even so, there are often multiple missed opportuni-
ties prior to a diagnosis of childhood TBM58. Since it can be 
challenging to identify bacilli in paediatric extrapulmonary 
TB, the use of host or pathogen biomarkers to aid diagnosis is 
being explored. Host biomarker-based tests have shown prom-
ise in extrapulmonary TB outside of the CNS and therefore have 
potential applications in TBM59. Recent technological advances 
have made it possible to screen for many biomarkers in as 
little as 3 μl of sample using the Luminex multiplex cytokine 
beaded arrays, albeit in research context currently, rather than 
routine clinical practice.
A three-marker CSF biosignature comprising IL-13, VEGF 
and cathelicidin LL-37, diagnosed childhood TBM with a 
sensitivity of 52%, specificity of 95%, with positive and negative 
predictive values of 91% and 66% respectively. Cut-off values 
for VEGF, IL-13 and cathelicidin LL-37 were 42.92 pg/mL, 
37.26 pg/mL and 3221.01 pg/mL respectively13. Further evalu-
ation of this three-marker CSF biosignature in a different 
cohort revealed positive and negative predictive values of 90% 
and 59.5% respectively, however with different cut-off values 
for VEGF, IL-13 and cathelicidin LL-37 of 9.4 pg/ml, 524.9 pg/
ml and optical density of 0.045 respectively60. In a study inves-
tigating potentially useful host biomarkers in CSF for child-
hood TBM (23 children with TBM and 24 controls), 28 proteins 
including IFN-γ, TNF-α, MPO, MMP-8, MMP-9, MIP-4 and 
CXCL9 amongst others, when analysed individually, showed 
areas under the receiver-operating curve (AUC) ≥0.80. When 
combined, biomarkers IFN-γ, MPO and VEGF showed good 
accuracy (AUC = 0.97, up to 91.3% sensitivity and up to 
100% specificity), as well as ICAM-1, MPO, CXCL8, and 
IFN-γ (AUC of 0.97, up to 87.0% sensitivity and up to 95.8% 
specificity). Cut-off values for VEGF, IFN-γ, MPO, ICAM-1 
and CXCL8 were >9.4 pg/ml, >99.5 pg/ml, >25823.0 pg/ml, 
>1372.0 pg/ml and >394.8 pg/ml, respectively60.
Despite the potential of CSF-based biosignatures, collec-
tion of CSF is invasive, and blood or urine-based inflammatory 
biosignatures require exploration. In a study evaluating 
serum biomarkers, the combination of CRP, IFN-γ, IP-10, 
CFH, Apo-A1 and SAA showed moderate diagnostic accu-
racy for clinically-defined TBM, including both ‘definite’ and 
Figure 4. Novel Host and Pathogen biomarkers for diagnosis of tuberculous meningitis50–56. LAM = lipoarabinomannan, RNA = 
riboneucleic acid, VOC = volatile organic chemicals, IGRA = inferferon gamma resease assay, DLL1 = delta-like ligand 1, VDBP = vitamin d 
binding protein, ADA = adenosine deaminase. * This image focuses only on novel host or TB biomarkers for diagnosis of TBM and does not 
incorporate traditional tools such as culture or AFB smear, or newer nucleic acid amplification tests in use commonly such as GeneXpert or 
GeneXpert Ultra, or experimental techniques such as metagenomic next generation sequencing.
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‘probable’ TBM (AUC of 0.75, sensitivity of 69.6% and specifi-
city of 62.5%). A three-biomarker combination of adipsin, Aβ42 
and IL-10 showed improved accuracy (AUC of 0.84, sensitivity 
of 82.6% and specificity of 75.0%). Cut-off values for CRP, 
IFN-γ, IP-10, CFH, Apo-A1, SAA, adipsin, Aβ42 and IL-10 were 
>80721.0 ng/ml, <61.5 pg/ml, <57.2 pg/ml, >350185.0 ng/ml, 
>287512.0 ng/ml, >59894.0 ng/ml, <2393.0 ng/ml, <278.4 pg/ml 
and <7.0 pg/ml, respectively. Although sample size was small, 
these biomarkers warrant further exploration61.
Pathogen-based diagnostics
The absence of a perfect gold standard for use in TBM diag-
nostic studies means that the results must be interpreted with 
an awareness of the pros and cons of the reference standard 
used. The 2010 uniform TBM case definition which defines 
cases as ‘definite’, ‘probable’, ‘possible’ or ‘not TBM’ is the 
most standardised tool to use when defining a case definition57. 
This case definition was derived by expert consensus rather 
than being data-driven and may therefore perform better in 
some contexts than others. In HIV-negative populations a refer-
ence standard of ‘definite, probable or possible’ is often used, 
however in PLWHIV including ‘possible’ in the reference 
standard can be imprecise due to the wide variety of infectious 
and non-infectious aetiologies that can fall into this category. It 
must also be noted that the potential to score points is affected 
by the ability to comprehensively investigate patients with 
brain, chest and abdominal imaging as well as microbiological 
sampling from outside the CNS; in resource constrained 
settings the ability to score a high number of points may there-
fore be compromised. We advocate use of the case definition to 
standardise results, allow for greater comparison between 
studies and meta-analysis of data; use of other standards must 
be interpreted with a degree of caution.
Nucleic-acid amplification tests. 
To address the limitations of conventional microscopy and cul-
ture techniques, NAATs have emerged as important tools for 
rapid and accurate diagnosis of TBM39. A recent meta-analysis 
evaluating NAATs in TBM reported heterogeneity in results 
with a pooled sensitivity of 82% against culture and 68% against 
a clinical reference standard62. This variability, especially in in-
house NAATs, is subject to difference in volume of sample, 
method of extraction, choice of targets used, presence of inhibi-
tors in the sample and lack of optimal reference standard. Tradi-
tional NAATs require expensive equipment, stringent operational 
conditions and technical expertise limiting their use in routine 
clinical practice in lower-resource, high endemic settings. To cir-
cumvent these challenges, loop mediated isothermal amplification 
(LAMP) assays were developed and can be conveniently carried 
out under isothermal conditions in an ordinary laboratory water 
bath or heating block within one hour. Though LAMP has 
outperformed PCR in an Indian study on TBM63, the assay is 
still in its infancy and needs further validation. Another method 
to potentially reduce the overall cost of NAAT would be to 
utilize magnetic bead assay technology, thus obviating the need 
of gel electrophoresis system or expensive dyes.
Xpert is a rapid (90 min run-time) fully-automated cartridge-
based real-time PCR assay that detects the presence of M.tb 
complex DNA, as well as rpoB gene mutations responsible for 
rifampicin resistance. The pooled sensitivity and specificity of 
Xpert against culture in 33 studies on TBM, was 71.1% and 
98%, respectively64. Xpert has been shown to significantly 
increase microbiological confirmation of TBM in Uganda over a 
6.5-year period but its impact on clinical outcomes in unknown65. 
Individual studies have also found inferior performance for 
Xpert compared to multiplex PCR66 or Amplicor assay67 in diag-
nosing TBM although these results have not been confirmed. 
The next generation, GeneXpert MTB/Rif Ultra (Ultra) has 
an 8-fold lower limit of detection than Xpert (16 CFU/ml ver-
sus 113 CFU/ml) attributable to a larger chamber allowing 
double the volume of sample to reach the PCR reaction and 
two additional DNA probes (IS1081 and IS6110)68. Ultra has 
demonstrated a sensitivity of 95% against a composite micro-
biological reference and 70% against probable/definite TBM 
in comparison to 45% and 43%, respectively for each Xpert and 
culture69,70. Ultra is endorsed by the WHO as the best initial test 
for TBM and is being rolled out currently, superseding Xpert71. 
The number of copies of IS1081 and IS6110 genes 
varies by M.tb strain and lineage, therefore the performance of 
the assay could potentially vary based on local strain patterns, 
highlighting the importance of local evaluation of diagnos-
tic performance as the assay is rolled out. Importantly, negative 
predictive value does not appear to be adequate to rule-out 
TBM with Ultra. Another commercial NAAT, the MTBDRplus 
assay, has been evaluated only in few cases of TBM and needs 
further validation72. Accurate and rapid detection of drug resist-
ance is another challenge, rifampicin resistance detection by Xpert 
has imperfect sensitivity (93%) and where detected and ideally 
requires confirmation by sequencing or culture66,73. Ultra uses 
melt curve analysis to improve detection of rifampicin resistance 
but both are about 95% sensitive74,75. Ultra will not be able 
to adequately define rifampin resistance in samples with a low 
quantity of bacilli (trace category positive)76. In summary NAATs, 
are a major diagnostic advance but they cannot yet fully replace 
culture methods. Ultra is too insensitive to rule out TBM, and 
like Xpert, should be considered as the first test and not the last in 
TBM diagnosis77. Ultra is an important step in the right direc-
tion but the result should be considered in the context of the 
clinical probability of TBM78.
CRISPR-MTB and metagenomic next generation sequenc-
ing. Clustered regularly interspaced palindromic repeat 
(CRISPR) associated proteins (Cas) have the ability to cleave 
DNA at specific sites and are being used widely in gene-editing 
and more recently in infectious disease diagnostics. When 
combined with DNA amplification, the CRISPR system can 
detect nucleic acid molecules at extremely low abundance. 
There is one recent report of utilizing the CRISPR system for 
detection of M.tb (CRISPR-MTB). The study included 26 CSF 
specimens and found CRISPR-MTB to have a sensitivity of 
73% compared to 54% for Xpert and 23% for culture against 
a reference standard of ‘clinical TBM’. The specificity of the 
test was 98% when tested against 63 non-TB cases. CRISPR-MTB 
is isothermal and can be performed in under 2 hours using only 
500 μl of CSF. CRISPR-MTB remains to be tested against 
Ultra and requires a higher level of laboratory expertise, 
resources, and time than the Xpert platform but may be an 
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advance in TB diagnostics if these findings can be confirmed 
in other settings with more standardized reference stanrdards79.
Metagenomic next generation sequencing (mNGS) is a rap-
idly developing technology that has proved useful in determin-
ing aetiologies for CNS infections that have evaded detection 
by conventional techniques. Further, mNGS, as opposed to 
organism-specific molecular tests has the ability to detect any 
low abundance infection with a single test80. A recent small 
study applied mNGS to stored CSF samples from 23 TBM 
cases and found a sensitivity of 67% (8/12) against a reference 
standard of definite TBM, higher than AFB stain (33%, 4/12), 
PCR (25%, 3/12) and culture (8%, 1/12)81. Paucibacillary condi-
tions such as TBM where the bacillary load may fall below the 
LOD of commercial NAATs, or where mutations exist around 
specific PCR primer binding sites may find particular use for 
mNGS. Targeted enrichment of low abundance genes with Find-
ing Low Abundance Sequences by Hybridization (FLASH), a 
novel CRISPR-Cas9 technology can increase DNA read abundance 
by up to 105-fold before sequencing occurs82. Combining 
FLASH and mNGS technologies could improve detection of 
TB DNA and associated antimicrobial resistance mutations 
mutations83. A first pilot of FLASH technology in TB dem-
onstrated up to a 100-fold increase in TB read abundance, 
detection of 6/6 cases of TBM positive with Ultra and detec-
tion of an additional case of TBM that had been missed by 
Xpert, Ultra and MGIT culture84. Here again, large studies need 
to be performed to better understand this technology’s per-
formance and the cost, laboratory infrastructure, and degree of 
expertise will need to be improved upon to permit widespread 
usage.
Pathogen-based biomarkers. A urine lateral flow assay (LFA) 
that detects M.tb lipoarabinomannan (TB-LAM), a 17 kDa 
glycolipid found in the outer cell wall of MTB, has recently 
been recommended by the World Health Organization for the 
diagnosis of HIV-associated TB in HIV-positive inpatients 
(Alere Determine TB-LAM, Abbott, Chicago, USA). The 
unique characteristic of the test is that its sensitivity increases as 
CD4 T-cell count falls, with a sensitivity of 56% in those with 
CD4 <100 cells/ml56. Yet, in CSF, despite some initial optimism 
related to an autopsy-based study in Uganda, the Alere TB-LAM 
has shown poor sensitivity on lumbar CSF in Uganda85,86, 
along with a larger Zambian study which examined culture posi-
tive TBM in Zambia (TB-LAM sensitivity 22% (23/105))85,87. 
The Alere TB-LAM is also limited by is susceptibility to 
individual reader interpretation of the darkness of the test line 
compared to the reference card (Figure 4). A novel LAM assay 
(Fujifilm SILVAMP TB-LAM, Fujifilm, Japan) is able to detect 
concentration of LAM at approximately 30-fold lower than 
Alere TB-LAM due to design differences, including a silver 
amplification step and gives a result in one hour88. The Fuji-
film LAM was recently tested on 968 urine samples (600 with 
definite pulmonary TB) in South Africa and showed a sensitivity 
of 70% (95% CI 53 - 83%) compared to 42% (95% CI 32 - 52%) 
for the Alere TB-LAM against a microbiological reference 
standard88. There is no data on this assay for diagnosis of TBM 
published to date.
Clinical prediction rules. 
Work is underway to develop a more accurate multivariable 
clinical prediction rule derived from large international cohorts 
using individual patient data89. The hope is that a data-driven 
scoring system will be developed for use in a range of clini-
cal settings by using common, readily available clinical or 
laboratory parameters to aide in clinical decision making.
Discussion
In the last five years, the pathogenesis of TBM has been 
better elucidated, in part thanks to detailed immunological 
studies on clinical samples preemptively stored during clini-
cal trials. These advances highlight the importance of collecting 
and storing samples appropriately for future research to maxi-
mize scientific outputs, as highlighted in the paper on sampling 
strategies in this collection. HIV infection is a major predictor 
of mortality in TBM and advanced HIV infection (CD4 T cell 
count <150 cell/μl) appears to drive a dysregulated, hyperinflam-
matory phenotype with very poor outcomes. In HIV-endemic 
sub-Saharan African settings around 90% of all adult TBM 
occurs amongst HIV-positive individuals65,90, often with either 
untreated advanced HIV or having recently initiated ART - both 
driving a hyperinflammatory response. In Vietnamese adults 
with TBM, LTA4H genotype is a strong predictor of mortality 
though this finding was not duplicated in Indonesia.
Recent insights have shown that neutrophils play a significant 
role in the immunopathogenesis of TBM, and that both a pau-
city and an excess of inflammation can be equally damaging in 
TBM. It has become increasingly clear that a ‘one-size-fits-all’ 
approach is too simplistic in TBM treatment, as in other infec-
tions such as pulmonary TB and sepsis91,92. The damage-response 
framework may provide a useful structure for understanding 
host-pathogen interactions in TBM, illustrating how immune 
response could be exploited for therapeutic purposes. Addi-
tional anti-inflammatory therapy with aspirin93,94 or more targeted 
immunotherapy could have a role in persons with an excessive 
inflammatory response; whilst individuals with an inadequate 
response might do better without corticosteroid treatment 
or might even benefit from immunomodulating therapy to 
boost their immune response95. Future trials of novel specific 
host-directed therapies are needed and must include immune 
markers to allow for post-hoc identification of subgroups 
benefitting from the initiated therapy. Because of the lack of 
correlation between blood and CSF compartments we advocate 
inclusion of both blood and CSF markers when studying 
adjuvant therapies.
The field of TBM diagnosis is rapidly evolving with GeneXpert 
MTB/Rif Ultra being the most promising test to date for diag-
nosis of TBM. Ultra is rapid and has potential to confirm more 
cases of TBM at lower bacillary loads, though whether this 
will improve outcomes remains to be determined. Most impor-
tantly, Ultra does not appear to have adequate predictive value 
to ‘rule-out’ TBM and so it cannot meet the potential of an 
ideal TBM diagnostic test to avoid long, toxic TBM therapy 
in persons without TBM. Novel sequencing technologies hold 
potential to provide increased understanding of pathogen 
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genomics and behavior and further illuminate host response, 
which may in turn lead to novel diagnostic and therapeutic 
targets. Sequencing technologies are increasingly available 
in TB endemic settings but will need further improvements 
in affordability and speed in addition to more data on accu-
racy to unlock their potential as diagnostic tools for TBM. 
It is now a realistic hope that a test (or set of tests) will one 
day be available that will be able to confirm or rule out TBM, 
provide M.tb resistance information, and direct clinicians 
to targeted, adjunctive host-directed therapy within hours.
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General comments
This is a comprehensive review of TB meningitis pathogenesis and diagnostics with the stated aim of
concentrating on the most recent developments (last 5 years).
The authors should be commended on providing a detailed review. They have included the vast majority
of recently published studies but should also include the Vietnamese study published in Lancet ID this
month by Donovan et al that compares Xpert against XpertUltra in TBM (and compare it to their recently
published study in HIV-TBM patients).
My main criticism of the review relates to the section on   which requires further workTBM pathogenesis
to improve understanding for the reader. There are several sections where the authors have listed a
series of findings from separate immunological studies but do not introduce the concept fully to the reader
and do not draw the findings together at the end of each section to provide an overall interpretation or
explanation for the reader. Some further explanation around these concepts would significantly improve
the review.
This is particularly true for the section covering host genetic factors and the influence of LTA4H genotype
on host response and outcome. This is a really important and fascinating piece of science but for readers
not already familiar with this concept this section is confusing. The authors should provide further
explanation, particularly regarding the differing inflammatory states associated with the three genotypes,
and why it is important. They should consider including discussion and reference of the original paper by
Tobin et al (Cell 2012).
Specific comments: 
Introduction
The GeneXpert test performances should be referenced. I think there is a typo on line 7
1
2
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 The GeneXpert test performances should be referenced. I think there is a typo on line 7
("traditional" should be "traditionally")?
TBM pathogenesis - Dissemination to the CNS
The use of the word  with regard to the Rich focus theory of TBM pathogenesis could berefute 
regarded as a bit strong. Do the authors think that the references provided fully support this
statement?
TBM pathogenesis - Host immune response to TB infection in the CNS
The first two sentences of the first paragraph in this section should probably contain a reference.
 
In the second paragraph, the association between death and lower CSF leukocyte count should
include the p=value.
 
Further explanation/interpretation of the lipid mediator findings and flow cytometery findings would
help improve understanding of this section.
 
The authors should also consider discussing the Vietnamese phase II trial of Aspirin by Mai et al
(Ref 94), further in this section. They very briefly mention it in the Discussion section but a more
detailed discussion is probably warranted and it may be appropriate to do so here.
TBM pathogenesis - Host genetic and metabolic factors.
As mentioned above, for readers not familiar with the original studies this section discussing
LTA4H genotypes is difficult to understand as it is currently written. It would benefit from re-wording
and further explanation, particularly a sentence or two to introduce the concept at the beginning of
the paragraph and a precise explanation of the effects of LTA4H genotype on inflammation, steroid
responsiveness and outcome (with reference to the original paper, Tobin et al. Cell.  2012).
 
The authors should also consider adding a couple sentences to the section on tryptophan to
provide some additional information about this study and providing a more comprehensive
explanation for the association between low levels and better survival.
Figure 2.
The figure should make it clear that the patients in A and B have all received steroids. It would also
aid understanding if the figure legend also contained the p=values with respect to the differing
outcomes quoted for graph A and B. The final sentence looks like it might contain a typo:
"In a recessive model, combined had HR 0.81 (95% CI 0.41-1.62, p =TT genotype versus CT/TT 
.550) in severe and 0.31 (95% CI 0.04-2.25, p = .156) in milder disease." 
I think the comparison stated in the model should be be  ?TT vs CT/CC
TBM pathogenesis - HIV co-infection and IRIS
In the first paragraph (line 9, copied below), a comparison in neutrophil counts and mortality is
presented between patients with a CD4 count >150, CD4 <150 and HIV negative.
"PLWHIV with CD4+ T-cell counts <150 cells/μL showed higher median CSF neutrophil
percentage (25%), cytokine concentrations and 9-month mortality (44%) than those with a CD4+
T-cell count ≥150 cells/μL (neutrophils 10%; , mortality 13%) and patients without HIVP=.021
infection (neutrophils 5%;  mortality 18%). These findings, amongst others, suggest a roleP<.0001,
2
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 infection (neutrophils 5%;  mortality 18%). These findings, amongst others, suggest a roleP<.0001,
for neutrophils in the immunopathogenesis of HIV-associated TBM."
However, there are only two p values included and it is not clear whether they refer to neutrophils
or mortality. Could the authors please alter this to make it a little clearer (and if appropriate add the
two additional p-values).
TBM pathogenesis - Pathogenesis of TBM in childhood
I don't think this section in its current form particularly adds to the review and there is no new data. I
would suggest this section is either expanded (to further discuss the differences between adult and
paediatric patients with TBM and the pathological processes underlying these differences) or
dropped. If the authors do decide to drop it they could consider amalgamating the statements
about Donald and Schoeman's TBM and milary TB findings into the earlier section: "Dissemination
to the central nervous system".
TBM pathogenesis - Brain injury markers
This paragraph would also benefit from further explanation so that the reader can appreciate the
importance of the findings. Further detail about the brain injury markers S100B and NSE would be
helpful (particularly whether they are used in other neurological conditions). Further text is also
required to explain what the CSF transcriptomic signature means.
TBM pathogenesis - Neuroimaging in pathogenesis studies
Is there a comma missing here?: "anterior cingulate gyrus parahippocampal gyrus and globus
pallidus".
 
The novel imaging studies reporting structural damage in cortical and subcortical areas are
interesting. Perhaps the authors could expand slightly to suggest the potential implications of this?
TBM pathogenesis - Host pathogen interactions.
This section discusses the damage response framework concept and applies it to TBM. I am not
sure why the first sentence includes data on global latent TB prevalence - it doesn't seem directly
relevant to this section.
 
It may improve the review if the authors expanded this section slightly and used it as a summary to
draw together all the immunological findings discussed above. Particularly to draw attention to the
importance of neutrophils.
TBM diagnostics
This section provides a good summary of host-based and pathogen-based diagnostics and reads
well.  
 
With regard to the host-based biomarkers, some of the pooled sensitivities appear promising but
have drawbacks. It would be useful if the authors could provide a concluding comment at the end
of the section discussing whether there is any future in these modalities (e.g. are any of those
mentioned being taken forward into further trials? Are there any plans to introduce any of these
tests?).
 
Regarding the performance of XpertUltra in TBM. The authors have mentioned their prospective
study examining its performance in Uganda (reference 70). They should emphasize that these
results were in patients with HIV infection. They should also mention the similar study from Vietnam
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 results were in patients with HIV infection. They should also mention the similar study from Vietnam
published alongside theirs this month in Lancet ID by Donovan et al which reports lower
sensitivities and no significant improvement on Xpert. They should discuss why this might be.
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